RD13-01 cell infusion

DRUG2 trials

Sponsors

He Huang, Min Xiang

Conditions

Hematologic MalignanciesT Acute Lymphoblastic LeukemiaT-lymphoblastic Lymphoma

Phase 1

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

CompletedNCT04538599

He HuangHematologic Malignancies

Start: 2020-09-10End: 2021-11-30Updated: 2022-01-25

Unknown Phase

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Min XiangT Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma

Start: 2020-11-15End: 2022-11-15Target: 24Updated: 2020-11-09

Related Papers

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood2025-11-03

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood2025-11-03

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Blood2025-11-03

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

New England Journal of Medicine2024-04-2490 citations

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood2023-11-023 citations

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Blood2022-11-1517 citations

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.

2022-09-23139 citations